JP2019527561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527561A5 JP2019527561A5 JP2019516285A JP2019516285A JP2019527561A5 JP 2019527561 A5 JP2019527561 A5 JP 2019527561A5 JP 2019516285 A JP2019516285 A JP 2019516285A JP 2019516285 A JP2019516285 A JP 2019516285A JP 2019527561 A5 JP2019527561 A5 JP 2019527561A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding portion
- cancer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 7
- 229940127121 immunoconjugate Drugs 0.000 claims 7
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 6
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 229910052776 Thorium Inorganic materials 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 claims 1
- 229940125666 actinium-225 Drugs 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 claims 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920001577 copolymer Chemical group 0.000 claims 1
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 102000046689 human FOLH1 Human genes 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000012038 nucleophile Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000000941 radioactive substance Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022183458A JP7564176B2 (ja) | 2016-06-06 | 2022-11-16 | 抗体、その使用及びそのコンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1609866.7 | 2016-06-06 | ||
| GBGB1609866.7A GB201609866D0 (en) | 2016-06-06 | 2016-06-06 | Antibodies, uses thereof and conjugates thereof |
| GB1708105.0 | 2017-05-19 | ||
| GBGB1708105.0A GB201708105D0 (en) | 2017-05-19 | 2017-05-19 | Antibodies, uses thereof and conjugates thereof |
| PCT/GB2017/051638 WO2017212250A1 (en) | 2016-06-06 | 2017-06-06 | Antibodies, uses thereof and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183458A Division JP7564176B2 (ja) | 2016-06-06 | 2022-11-16 | 抗体、その使用及びそのコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527561A JP2019527561A (ja) | 2019-10-03 |
| JP2019527561A5 true JP2019527561A5 (enExample) | 2020-07-09 |
| JP7179719B2 JP7179719B2 (ja) | 2022-11-29 |
Family
ID=59062044
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516285A Active JP7179719B2 (ja) | 2016-06-06 | 2017-06-06 | 抗体、その使用及びそのコンジュゲート |
| JP2022183458A Active JP7564176B2 (ja) | 2016-06-06 | 2022-11-16 | 抗体、その使用及びそのコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183458A Active JP7564176B2 (ja) | 2016-06-06 | 2022-11-16 | 抗体、その使用及びそのコンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11485792B2 (enExample) |
| EP (2) | EP4282434A3 (enExample) |
| JP (2) | JP7179719B2 (enExample) |
| CN (2) | CN117534764A (enExample) |
| ES (1) | ES2965349T3 (enExample) |
| WO (1) | WO2017212250A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200130709A (ko) * | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
| SG11202009670RA (en) * | 2018-03-29 | 2020-10-29 | Ambrx Inc | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
| CN119405833A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| CN120189526A (zh) | 2018-12-13 | 2025-06-24 | 卫材R&D管理有限公司 | 荷伯希二烯抗体-药物缀合物及使用方法 |
| EP3994177A4 (en) * | 2019-07-02 | 2023-09-20 | Telix International Pty Ltd | PSMA-BINDING ANTIBODIES WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR |
| CN114729059A (zh) | 2019-09-11 | 2022-07-08 | 宾夕法尼亚大学董事会 | 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法 |
| AU2021206218A1 (en) * | 2020-01-06 | 2022-07-07 | Cytomx Therapeutics, Inc. | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
| MX2022011808A (es) * | 2020-03-25 | 2022-12-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Conjugado de anticuerpo anti-psma-analogo de exatecan y uso medico del mismo. |
| CN113234437B (zh) * | 2021-05-14 | 2022-04-26 | 西北师范大学 | 基于金属有机骨架的比率荧光探针的制备和在检测1,4-二硫苏糖醇中的应用 |
| US20230022596A1 (en) * | 2021-06-18 | 2023-01-26 | Clarence Hurt | Neoantigen-eliciting antibody drug conjugates for the immunotherapy of cancer |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
| CN116271081A (zh) * | 2023-04-04 | 2023-06-23 | 上海愿智生物技术有限公司 | 一种抗体偶联药物yc1605及其药物组合物和应用 |
| EP4750803A1 (en) | 2023-07-25 | 2026-06-03 | Cymab ApS | Antigen-binding molecules capable of binding interferon gamma |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| CN1294588C (zh) | 1996-07-24 | 2007-01-10 | 皇家菲利浦电子有限公司 | 光盘录取装置 |
| US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| CA2447695C (en) | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| US20100239517A1 (en) | 2007-10-09 | 2010-09-23 | Stephen Brocchini | Novel conjugated proteins and peptides |
| US20110311550A1 (en) | 2008-10-24 | 2011-12-22 | The Scripps Research Institute | Agents for hcv treatment |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| CA3040276A1 (en) | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| NO2789793T3 (enExample) | 2012-10-24 | 2018-01-27 | ||
| ES2623209T3 (es) | 2012-10-24 | 2017-07-10 | Polytherics Limited | Conjugados fármaco-proteína |
| DK3151865T3 (da) | 2014-05-22 | 2021-10-25 | Byondis Bv | Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs |
| WO2016033547A1 (en) | 2014-08-29 | 2016-03-03 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind oprf and oprl |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| EP3220956B1 (en) | 2014-10-24 | 2023-08-09 | Abzena (UK) Limited | Conjugates and conjugating reagents |
-
2017
- 2017-06-06 CN CN202311507569.2A patent/CN117534764A/zh active Pending
- 2017-06-06 WO PCT/GB2017/051638 patent/WO2017212250A1/en not_active Ceased
- 2017-06-06 ES ES17730240T patent/ES2965349T3/es active Active
- 2017-06-06 CN CN201780035044.XA patent/CN109311996B/zh active Active
- 2017-06-06 EP EP23199243.9A patent/EP4282434A3/en active Pending
- 2017-06-06 JP JP2019516285A patent/JP7179719B2/ja active Active
- 2017-06-06 US US16/303,596 patent/US11485792B2/en active Active
- 2017-06-06 EP EP17730240.3A patent/EP3464379B1/en active Active
-
2022
- 2022-11-16 JP JP2022183458A patent/JP7564176B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535232A5 (enExample) | ||
| Wang et al. | Advances in PSMA-targeted therapy for prostate cancer | |
| Cimadamore et al. | New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen | |
| Wängler et al. | Antibody− dendrimer conjugates: The number, not the size of the dendrimers, determines the immunoreactivity | |
| Kiess et al. | Prostate-specific membrane antigen as a target for cancer imaging and therapy | |
| Wang et al. | Development of targeted near-infrared imaging agents for prostate cancer | |
| Mansi et al. | Targeting GRPR in urological cancers—from basic research to clinical application | |
| Ristau et al. | The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research | |
| Hong et al. | Positron emission tomography imaging of prostate cancer | |
| JP5739880B2 (ja) | ＩｇＧ結合のための部位を同定するための方法 | |
| AU2010325969B2 (en) | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen | |
| Westerlund et al. | Increasing the net negative charge by replacement of DOTA chelator with DOTAGA improves the biodistribution of radiolabeled second-generation synthetic affibody molecules | |
| US11801307B2 (en) | Antibody-polymer-drug conjugates | |
| JP2015523326A5 (enExample) | ||
| WO2007100385A3 (en) | Macrocyclic depsipeptide antibody-drug conjugates and methods | |
| MX2021010003A (es) | Anticuerpos anti-mertk de alta afinidad y usos de los mismos. | |
| Maina et al. | From bench to bed: New gastrin-releasing peptide receptor-directed radioligands and their use in prostate cancer | |
| JP2018516854A5 (enExample) | ||
| ME02919B (me) | Konjugati humanog antitijela sa lijekom protiv tkivnog faktora | |
| Luo et al. | Dual targeting of tissue factor and CD105 for preclinical PET imaging of pancreatic cancer | |
| Peng et al. | Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer | |
| Olson et al. | Antibody-drug conjugates targeting prostate-specific membrane antigen | |
| Luca et al. | Peptide ligands specifically targeting HER2 Receptor and the role played by a synthetic model system of the receptor extracellular domain: Hypothesized future perspectives | |
| KR20230065935A (ko) | 치료적 접합체 | |
| JP2016528299A5 (enExample) |